Serpina1 iRNA compositions and methods of use thereof

US10683504B2 · kind B2 · utility

Assignee

• Alnylam Pharmaceuticals, Inc. · US

Inventors

• Alfica Sehgal · Cambridge, US
• Klaus Charisse · Acton, US
• Brian Bettencourt · Groton, US
• Martin Maier · Cambridge, US
• Kallanthottathil G. Rajeev · Wayland, US
• Gregory Hinkle · Plymouth, US
• Muthiah Manoharan · Carlsbad, US

Key dates

• Filing date: Nov 11, 2019
• Grant date: Jun 16, 2020
• Expiry date: Nov 11, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2330/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.